Lurbinectedin

Mechanism of Action

Lurbinectedin is an antineoplastic agent that belongs to the class of drugs called alkylating agents. It works by inducing DNA damage and blocking DNA repair, leading to cell death in cancer cells.

The mechanism of action of lurbinectedin involves the binding of the drug to DNA and the formation of covalent bonds with the DNA molecule. This binding leads to the formation of DNA adducts, which interfere with the normal functioning of DNA, including DNA replication and transcription.

Lurbinectedin specifically targets a type of RNA transcription called ""RNA polymerase II termination factor (RTF)"" which is overproduced in certain cancer cells. By inhibiting RTF, lurbinectedin causes the accumulation of RNA polymerase II on the DNA, leading to DNA damage and the eventual death of the cancer cell.

Indication

Lurbinectedin is a chemotherapy drug that is indicated for the treatment of advanced small cell lung cancer (SCLC) in adult patients with disease progression on or after platinum-based chemotherapy. It is also indicated for the treatment of adult patients with relapsed and refractory small cell lung cancer (RR-SCLC) who have received at least two prior lines of therapy.

It works by binding to and inhibiting the activity of an enzyme called RNA polymerase, which is important for the replication of cancer cells. This leads to the death of cancer cells and slows the progression of the disease.

Lurbinectedin should be administered under the supervision of a qualified healthcare provider experienced in the administration of cancer chemotherapy. It is important to carefully follow the dosing and administration instructions provided by your healthcare provider.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Lurbinectedin API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Lurbinectedin API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.